Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome
Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS). However, there are few studies evaluating eculizumab therapy among children with HUS. The primary ob...
Main Authors: | Saritha Ranabothu, Clare C. Brown, Richard Blaszak, Rachel Millner, Kristen Rice Moore, Parthak Prodhan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2021.733042/full |
Similar Items
-
Hemolytic Uremic Syndrome; 10 Year Single Center Experience
by: Sibel YEL, et al.
Published: (2022-04-01) -
Rational use of eculizumab in secondary atypical hemolytic uremic syndrome
by: Lucía Cordero, et al.
Published: (2024-01-01) -
Rapid Resolution of Atypical Hemolytic Uremic Syndrome by Eculizumab Treatment
by: Min Seung Kim, et al.
Published: (2020-10-01) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
by: Seong Heon Kim, et al.
Published: (2018-02-01) -
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
by: Sara Madureira Gomes, et al.
Published: (2021-04-01)